ClinicalTrials.gg
CompletedNCT03659890FUNUpdated Mar 26, 2020

Dietary Nucleotides and Ribose on Muscle Fuel Utilisation

An interventional study of Low nucleotide and High nucleotide in Healthy, sponsored by University of Exeter. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-26.

Sponsored by University of Exeter · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Nucleotides are the building blocks for a variety of molecules, including ATP, which is broken down in the skeletal muscle cells to provide fuel for exercise. Nucleotides can be obtained from the diet, and produced or salvaged by the body. Though nucleotides provide the building blocks for ATP, the sugar ribose has been suggested to be rate limiting for synthesising ATP.

Previous studies have shown a decrease in ATP levels in the muscle after intense exercise, and this is linked to fatigue. Other studies have also reported benefits of nucleotide and/or ribose supplementation on exercise performance. However, any potential link between ATP metabolism and exercise performance has not been explored.

This study will look at the effects of nucleotide and nucleotide-ribose supplementation in fuel utilisation and performance in skeletal muscle during endurance exercise.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

University of Exeter is the lead sponsor of 140 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • BMI between 18 and 30

Exclusion criteria

Exclusion Criteria:

  • On medication (except contraception)
  • Smokers
  • Diagnosed with any metabolic or cardiovascular conditions
  • Muscle or bone injuries
  • BMI \< 18 or > 30
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
13 participants (actual)

Study arms

  • Placebo comparator
    Low nucleotide

    2 week supplementation with a low nucleotide mycoprotein drink, with added dextrose

    Dietary Supplement: Low nucleotide

  • Experimental
    High nucleotide

    2 week supplementation with a high nucleotide mycoprotein drink, with added dextrose

    Dietary Supplement: High nucleotide

  • Experimental
    High nucletide + Ribose

    2 week supplementation with a high nucleotide mycoprotein drink, with added ribose

    Dietary Supplement: High nucletide + Ribose

Interventions

  • Dietary supplementLow nucleotide

    2 week, twice daily, supplementation with a nucleotide-depleted mycoprotein drink, with added dextrose

  • Dietary supplementHigh nucleotide

    2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added dextrose

  • Dietary supplementHigh nucletide + Ribose

    2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added ribose

06

What researchers measure

Primary outcomes

  1. Changes in muscle ATP concentrations

    Time frame: After each supplementation cycle (day 15 of each cycle): baseline (fasted and before exercise), immediately after glycogen depleting exercise (after exercising for 1:30 - 2 hours), immediately after 15 minute time trial and after 3-hour recovery

Secondary outcomes

  1. Changes in muscle glycogen concentrations

    Time frame: After each supplementation cycle (day 15 of each cycle): baseline (fasted and before exercise), immediately after glycogen depleting exercise (after exercising for 1:30 - 2 hours), immediately after 15 minute time trial and after 3-hour recovery

  2. Blood lactate concentrations

    Time frame: After supplementation cycle (day 15): baseline and at 15 minute intervals up 1 hour during glycogen depleting exercise

  3. Blood glucose concentrations

    Time frame: After supplementation cycle (day 15): baseline and at 15 minute intervals up 1 hour during glycogen depleting exercise

  4. Serum uric acid concentrations

    Time frame: Measured at baseline and of days 6, 8 and 15 of each supplementation cycle

07

Study locations

1 site
  • University of Exeter - St Luke's Campus
    Exeter, Devon EX2 4TH, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Feb 2020, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2018
First posted
Sep 6, 2018
StartActual
Jun 28, 2018
Primary completionActual
Feb 2, 2020
CompletionActual
Feb 2, 2020
Last update
Mar 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03659890
Responsible party
Sponsor
First posted
Sep 6, 2018
Start date
Jun 28, 2018
Primary completion
Feb 2, 2020
Completion
Feb 2, 2020
Last update
Mar 26, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion